American Companies Hide Medical Research in China to Prevent Imitation

American biotech companies are increasingly adopting more secretive measures to protect their research from being quickly copied by Chinese firms, which demonstrate an ability to develop competitive drugs rapidly and at lower costs. This has led to reduced disclosure of clinical trial results, hindering funding and intensifying competition. The number of early-stage trials in China has grown fivefold compared to a decade ago, prompting American companies to acquire early Chinese innovations and to focus their efforts on reducing risks associated with information confidentiality.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل